The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's decision on semaglutide shortage.
Palantir Technologies have surged 19% this week, trading above $110 Friday afternoon. Investors have responded positively to a combination of geopolitical developments and major defense partnerships.
Shares of health coverage company Centene (NYSE:CNC)
fell 7.6% in the morning session after the company reported a mixed first-quarter 2025 performance: a decline in total customers and a slightly weaker full-year earnings outlook cast a shadow over the results. On the other hand, revenue and adjusted EPS both beat expectations. Overall, we think this was a weaker quarter.
Shares of transportation and logistics solutions provider Universal Logistics (NASDAQ:ULH)
fell 9.1% in the morning session after the company reported weak first-quarter 2025 results, as both revenue and EBITDA fell well below Wall Street's expectations. Sales fell across every major segment: contract logistics, the company's largest line, shrank 18%, while intermodal and trucking dropped nearly 10% and 20%, respectively.
Management acknowledged the sluggish start but pointed to improving trends later in the quarter, and emphasized plans to restructure underperforming operations and pursue new customer wins.
Still, with no guidance issued and visibility into a rebound unclear, the quarter offered little to ease concerns about the company's path back to growth.
Shares of life sciences company Avantor (NYSE:AVTR)
fell 21.2% in the afternoon session after the company reported a weak first-quarter 2025 performance, as its organic revenue and total sales both missed Wall Street's expectations. Sales dropped 6% from a year ago, reflecting softness across both major business segments. Lab Solutions declined 8% while Bioscience Production slipped slightly.
Encouragingly, management raised its cost savings target to $400 million by 2027 and signaled urgency to fix performance issues in the Lab Solutions segment.
Overall, this was a softer quarter.
Shares of cable, internet, and telephone services provider Charter (NASDAQ:CHTR)
jumped 11.2% in the afternoon session after the company reported strong first-quarter 2025 results, with earnings and EBITDA exceeding analysts' estimates, signaling improved cost control and solid profit growth. On the other hand, its number of internet subscribers missed. Zooming out, we think this was a decent quarter featuring some areas of strength but also some blemishes.
Curious about the top performers within the S&P500 index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of electric vehicle pioneer Tesla (NASDAQ:TSLA) jumped 10.4% in the afternoon session after the National Highway Traffic Safety Administration (NHTSA), rolled out new rules to speed up the launch of home-built self-driving cars. As part of this push, the group planned to cut red tape in crash reports, making it easier for firms like Tesla to test their autonomous vehicles. NHTSA also wants to stretch an old rule that lets some cars skip standard checks, so more US-made driverless cars can join. These moves were designed to offer a clear plan to put the US ahead in the autonomous vehicle market, especially as China steps up its game.
Shares of freight carrier Old Dominion (NASDAQ:ODFL)
fell 8.7% in the afternoon session after the company reported underwhelming first-quarter 2025 results, as a drop in revenue and earnings weighed on investor sentiment. Revenue fell nearly 6% year on year, driven by a decline in tonnage and shipment counts.
Overall, this was a weaker quarter.
Shares of HVAC and electrical contractor Comfort Systems (NYSE:FIX) jumped 11% in the pre-market session after the company reported stunning first-quarter 2025 results, which crushed earnings and backlog expectations, pointing to strong demand and solid execution in a typically soft seasonal period. Same-store backlog grew 16%, a massive jump that signaled growing confidence from customers and a robust pipeline of future projects. Zooming out, we think this was a solid quarter.
The S&P 500® Top 20 Select Index series launched in August 2024 and is designed to measure the capped market-capitalization-weighted performance of the largest 20 companies, by float market cap, in the S&P 500.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Shares of gaming and hospitality company Boyd Gaming (NYSE:BYD)
jumped 6.8% in the morning session after the company reported strong first-quarter 2025 results, with revenue, EBITDA, and earnings per share all coming in above Wall Street's expectations, despite weather disruptions and a tough comparison to last year's leap year bump. The real story was the 20% jump in online segment revenue, now a vital part of Boyd's growth engine, fueled by higher contributions from digital casino games.
Overall, this quarter had some key positives.
Shares of children’s apparel manufacturer Carter’s (NYSE:CRI)
fell 11.5% in the afternoon session after the company reported weak first-quarter 2025 results, as a narrow beat on adjusted EPS and stronger-than-expected same-store sales were overshadowed by its suspension of forward guidance amid a CEO transition and tariff uncertainty.
Shares of freight transportation and logistics provider Saia (NASDAQ:SAIA)
fell 34.8% in the afternoon session after the company reported weak first-quarter 2025 results, with its revenue and EBITDA both falling short of analysts' estimates, reflecting a tough start to the year. The real story was the sharp sales and profit declines, driven by weather-related disruptions, and weaker-than-expected March shipments.
While revenue ticked up 4%, that modest gain masked deeper issues: growth in tonnage and shipments was undermined by a drop in revenue per unit, especially when excluding fuel surcharges, which fell more than 5%. The lack of typical seasonal acceleration in March also weighed heavily on performance. Overall, this was a softer quarter.
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.
